ARVN•benzinga•
Reported Saturday, Arvinas and Pfizer's Vepdegestrant Demonstrates Statistically Significant 2.9-Month PFS Benefit Over Fulvestrant In ESR1-Mutant Second-Line Advanced Breast Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga